Retrospective Cohort Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. May 14, 2021; 27(18): 2177-2192
Published online May 14, 2021. doi: 10.3748/wjg.v27.i18.2177
Table 1 Baseline characteristics of patients with and without sustained virologic response and their relationship to treatment efficacy
Variable
Total, n = 11938
SVR, n = 11629
Non-SVR, n = 309
P value
Sex, n (%)
Male5762 (48.3)5553 (47.8)209 (67.6)< 0.001
Female6176 (51.7)6076 (52.2)100 (32.4)
Age52.24 (51.77-52.70)52.24 (51.77-52.71)52.16 (50.74-53.58)0.869
BMI (kg/m2)26.47 (26.29-26.64)26.45 (26.26-26.62)27.20 (26.68-27.72)< 0.001
Fibrosis
F0277 (1.9)225 (99.1)2 (0.9)
F14539 (38.8)4469 (98.5)70 (1.5)
F22249 (19.2)2204 (98.0)45 (2.0)< 0.001
F31717 (14.7)1684 (98.1)33 (1.9)
F42974 (25.4)2828 (95.1)146 (4.9)
Liver stiffness (kPa)12.72 (12.45-12.99)12.53 (12.29-12.76)20.27 (14.78-25.76)< 0.001
Child Pugh, n (%)
A11320 (96.9)11050 (97.1)270 (89.7)
B346 (3.0)315 (2.8)31 (10.3)< 0.001
C13 (0.1)13 (0.1)0 (0.0)
MELD score7.81 (7.76-7.85)7.79 (7.74-7.84)8.39 (8.11-8.67)< 0.001
Esophageal varices, n (%)
Yes989 (10.5)922 (10.1)67 (27.1)< 0.001
No8413 (89.5)8233 (89.9)180 (72.9)
Ascites at the start of the treatment, n (%)
No11742 (98.8)11444 (98.9)298 (96.4)
Moderate136 (1.2)125 (1.1)11 (3.6)< 0.001
Tense6 (0.0)6 (0.0)0 (0.0)
Encephalopathy at the start of the treatment, n (%)
No11808 (99.4)11507 (99.5)301 (97.8)
Grade 1-267 (0.6)60 (0.5)7 (2.2)0.001
Grade 3-41 (0.0)1 (0.0)0 (0.0)
History of hepatocellular carcinoma, n (%)
Yes179 (1.5)167 (1.5)12 (4.1)< 0.001
No11515 (98.5)11231 (98.5)284 (95.9)
Extrahepatic manifestations, n (%)
Yes948 (8.3)916 (8.2)32 (10.8)0.282
No10513 (91.7)10248 (91.8)265 (89.2)
HIV coinfection, n (%)
Yes587 (5.0)564 (4.9) 23 (7.6)0.098
No11161 (95.0)10881 (95.1)280 (92.4)
HBV coinfection, n (%)
Yes1570 (13.5)1526 (13.4)44 (14.6)0.851
No10098 (86.5)9840 (86.6)258 (85.4)
HBsAg(+), n (%))124 (8.0)122 (8.1)2 (4.5)0.543
Reactivation of HBV infection, n (%)
Yes11 (0.1)11 (0.1)0 (0.0)0.510
No10707 (99.9)10435 (99.9)272 (100.0)
History of liver transplantation, n (%)
Yes146 (1.2)144 (1.3)2 (0.7)0.576
No11555 (98.8)11253 (98.7)302 (99.3)
Course of treatment, n (%)
As planned11516 (97.1)11238 (97.3)278 (90.2)
Terminated early86 (0.7)71 (0.6)15 (4.9)< 0.001
Modified257 (2.2)242 (2.1)15 (4.9)
Ascites appearing while on treatment, n (%)
Yes64 (0.5)57 (0.5)7 (2.3)< 0.001
No11773 (99.5)11473 (99.5)300 (97.7)
Encephalopathy appearing while on treatment, n (%)
Yes43 (0.4)35 (0.3)8 (2.6)< 0.001
No11773 (99.6)11474 (99.7)299 (97.4)
Gastrointestinal bleeding while on treatment, n (%)
Yes16 (0.1)14 (0.1)2 (0.7)0.044
No11798 (99.9)11494 (99.9)304 (99.3)
Table 2 Baseline characteristics of patients with and without sustained virologic response and their relationship to treatment efficacy-laboratory parameters
Variable
Total, n = 11938
SVR, n = 11629
Non-SVR, n = 309
P value
Albumin (g/dL)4.37 (4.2-4.45)4.38 (4.29-4.46)4.02 (3.76-4.28)< 0.001
Bilirubin (mg/dL)0.80 (0.79-0.81)0.79 (0.78-0.80)1.06 (0.98-1.15)< 0.001
INR1.10 (1.07-1.12)1.10 (1.07-1.12)1.11 (1.08-1.13)< 0.001
PLT (K/μL)191.47 (190.07-192.85)192.62 (191.22-194.02)147.63 (139.07-156.19)< 0.001
ALT (U/L)78.39 (77.19-79.59)77.92 (76.71-79.13)96.07 (87.16-104.98)< 0.001
Creatinine (mg/dL)0.92 (0.89-0.96)0.93 (0.89-0.96)0.81 (0.79-0.83)0.749
eGFR, n (%)
< 30 mL/min137 (29.2)137 (29.7)0 (0.0)
> 60 mL/min160 (34.0)157 (34.0)3 (37.5)0.252
30-60 mL/min173 (36.8)168 (36.3)5 (62.5)
Hemoglobin (g/dL)14.40 (14.37-14.43)14.40 (14.37-14.44)14.35 (14.15-14.55)0.812
HCV genotype, n (%)
1A434 (3.6)426 (3.7)8 (2.6)
1B9327 (78.1)9147 (78.7)180 (58.3)
220 (0.2)20 (0.2)0 (0.0)< 0.001
31328 (11.1)1221 (10.5)107 (34.6)
4575 (4.8)565 (4.9)10 (3.2)
51 (0.0)1 (0.0)0 (0.0)
62 (0.0)2 (0.0)0 (0.0)
HCV RNA (log10)6.37 (6.34-6.39)6.36 (6.34-6.39)6.39 (6.31-6.46)0.004

  • Citation: Janczewska E, Kołek MF, Lorenc B, Klapaczyński J, Tudrujek-Zdunek M, Sitko M, Mazur W, Zarębska-Michaluk D, Buczyńska I, Dybowska D, Czauż-Andrzejuk A, Berak H, Krygier R, Jaroszewicz J, Citko J, Piekarska A, Dobracka B, Socha Ł, Deroń Z, Laurans Ł, Białkowska-Warzecha J, Tronina O, Adamek B, Tomasiewicz K, Simon K, Pawłowska M, Halota W, Flisiak R. Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study. World J Gastroenterol 2021; 27(18): 2177-2192
  • URL: https://www.wjgnet.com/1007-9327/full/v27/i18/2177.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v27.i18.2177